{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-006460","form_type":"8-K","ticker":"TRAW","cik":"0001130598","company_name":"Traws Pharma, Inc.","filed_at":"2026-01-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.597216+00:00","generated_at":"2026-05-16T07:49:12.145653+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Traws Pharma completes ratutrelvir Phase 2 enrollment; tivoxavir influenza prophylaxis study set for June 2026","bullets":["Ratutrelvir study fully enrolled (90 pts); shows fewer AEs, no viral rebound, faster symptom resolution vs PAXLOVID.","Separate arm for PAXLOVID-ineligible patients addresses high-risk group with few effective options.","Tivoxavir marboxil compressed tablet predicted to offer 28-day influenza protection; challenge study secured for June 2026 at hVIVO.","Ratutrelvir's profile may support future studies in reducing risk of Long COVID via early viral clearance.","CEO states advancement of antiviral portfolio provides significant value inflection points."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-006460","json":"https://secwatch.observer/filing/0001104659-26-006460.json","markdown":"https://secwatch.observer/filing/0001104659-26-006460.md","text":"https://secwatch.observer/filing/0001104659-26-006460.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1130598/000110465926006460/0001104659-26-006460-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1130598/000110465926006460/tm264027d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T07:49:12.145653+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}